Robert C Doebele
Overview
Explore the profile of Robert C Doebele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
139
Citations
11696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schubert L, Elliott A, Le A, Estrada-Bernal A, Doebele R, Lou E, et al.
Front Oncol
. 2023 May;
13:1115405.
PMID: 37168365
Purpose: Gene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for , , and gene fusions. Fusions involving...
12.
Schubert L, Le A, Hinz T, Navarro A, Nelson-Taylor S, Nemenoff R, et al.
bioRxiv
. 2023 Apr;
PMID: 37066347
CRISPR/Cas9 gene editing technology is an indispensable and powerful tool in the field of cancer biology. To conduct successful CRISPR-based experiments, it is crucial that sgRNAs generate their designed alterations....
13.
Hu Q, Liao Y, Cao J, Fang B, Yun S, Kinose F, et al.
Chembiochem
. 2023 Mar;
24(11):e202200766.
PMID: 36922348
Metastasis poses a major challenge in cancer management, including EML4-ALK-rearranged non-small cell lung cancer (NSCLC). As cell migration is a critical step during metastasis, we assessed the anti-migratory activities of...
14.
Chuang T, Lai W, Gabre J, Lind D, Umapathy G, Bokhari A, et al.
Proc Natl Acad Sci U S A
. 2023 Feb;
120(8):e2216479120.
PMID: 36791109
Anaplastic lymphoma kinase (ALK) fusion variants in Non-Small Cell Lung Cancer (NSCLC) consist of numerous dimerizing fusion partners. Retrospective investigations suggest that treatment benefit in response to ALK tyrosine kinase...
15.
Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis G, Mandell M, et al.
NPJ Precis Oncol
. 2023 Jan;
7(1):9.
PMID: 36690705
Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the...
16.
Gounder M, Bauer T, Schwartz G, Weise A, LoRusso P, Kumar P, et al.
J Clin Oncol
. 2023 Jan;
41(9):1714-1724.
PMID: 36669146
Purpose: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of milademetan, a small-molecule murine double minute-2 (MDM2) inhibitor, in patients with advanced cancers. Patients And Methods: In this...
17.
Rusch V, Nicholas A, Patterson G, Waqar S, Toloza E, Haura E, et al.
J Thorac Cardiovasc Surg
. 2022 Nov;
165(3):828-839.e5.
PMID: 36369159
Objective: Multimodality treatment for resectable non-small cell lung cancer has long remained at a therapeutic plateau. Immune checkpoint inhibitors are highly effective in advanced non-small cell lung cancer and promising...
18.
Tyler L, Le A, Chen N, Nijmeh H, Bao L, Wilson T, et al.
Thorac Cancer
. 2022 Sep;
13(21):3032-3041.
PMID: 36101520
Background: ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving...
19.
Ananthapadmanabhan V, Frost T, Soroko K, Knott A, Magliozzi B, Gokhale P, et al.
JCI Insight
. 2022 Jul;
7(13).
PMID: 35801592
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin with 2 etiologies. Merkel cell polyomavirus (MCPyV) integration is present in about 80% of all MCC. Virus-positive MCC...
20.
Bianco G, Coto-Llerena M, Gallon J, Kancherla V, Taha-Mehlitz S, Marinucci M, et al.
Commun Biol
. 2022 Jul;
5(1):658.
PMID: 35787660
No abstract available.